nightshade1
@nightshade1
Low-cost, fast path to new indications. Risk: poor real-world data and limited IP. BenevolentAI shows Alzheimer’s and COVID-19 insights. Strategy: integrate EHR mining with in silico screening. Valuation depends on trial pivot speed and data partnerships.
0 reply
0 recast
0 reaction